Evidence map›Paper›PMID 30228219›Full record

ArticleGut2019

ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.

Wenjia Wang, Scott C Friedland, Bing Guo, Michael R O'Dell, William B Alexander, Christa L Whitney-Miller, Diana Agostini-Vulaj, Aaron R Huber, Jason R Myers, John M Ashton and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Molecular interplay of ARID1A in gastrointestinal cancers.Medical oncology (Northwood, London, England) · 2025
    Review
  8. Article
  9. Review
  10. Therapeutic Role of Synthetic Lethality inJournal of immunotherapy and precision oncology · 2024
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. iScience · 2023
    Article
  17. The role of molecular testing in pancreatic cancer.Therapeutic advances in gastroenterology · 2023
    Review
  18. Review
  19. Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.Biochimica et biophysica acta. Reviews on cancer · 2023
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Wenjia Wang *Division of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-0336-9412
Scott C Friedland *Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York, USA.
Bing GuoDivision of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
Michael R O'DellDivision of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
William B AlexanderDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, New York, USA.
Christa L Whitney-MillerDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Diana Agostini-VulajDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Aaron R HuberDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Jason R MyersGenomics Research Center, University of Rochester Medical Center, Rochester, New York, USA.
John M AshtonGenomics Research Center, University of Rochester Medical Center, Rochester, New York, USA.
Richard F DunneDivision of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
Laurie A SteinerDepartment of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.
Aram F HezelDivision of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
University of Rochester Medical Center · US

Funding

Washington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9M
Genetics pathways in intra-hepatic cholangiocarcinomaR01CA172302 · NCI · UNIVERSITY OF ROCHESTER · PI HEZEL, ARAM F. · 2013 to 2017
$1.6M
NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA172302
6 · The paper itself

Abstract

objectiveHere, we evaluate the contribution of AT-rich interaction domain-containing protein 1A (

designMice with a targeted deletion of

results

conclusionsARID1A plays a key role in pancreatic acinar homeostasis and response to injury. Furthermore, ARID1A restrains oncogenic KRAS-driven formation of premalignant proliferative IPMN.

Indexed as

Acinar CellsAnimalsCarcinoma, Pancreatic DuctalCell ProliferationDisease Models, AnimalDNA-Binding ProteinsEpithelial-Mesenchymal TransitionHomeostasisMiceNuclear ProteinsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Transcription FactorsArid1a protein, mouseDNA-Binding ProteinsHras protein, mouseNuclear ProteinsProto-Oncogene Proteins p21(ras)Transcription Factorscancer geneticsepithelial differentiationpancreatic cancerpancreatic pathology

Identifiers

PMID30228219
PMCPMC6551318
OpenAlexW2890029692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.